Gamida Cell jumps on FDA lymphoma treatment clearance

• Published date: 26 April 2022
• Author: Globes correspondent
• Publication title: Globes (Rishon LeZion, Israel)

GDA-201 is an off-the-shelf cell therapy candidate for the treatment of patients with follicular and diffuse large B cell lymphomas. Gamida Cell expects to initiate a company-sponsored Phase 1/2 clinical study in patients with follicular and diffuse large B-cell lymphomas in 2022

The company develops NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases. Gamida Cell's NAM-enabling technology, supported by positive Phase III data, is designed to enhance the number and functionality of targeted cells, enabling the company to pursue a curative approach.

Gamida Cell CEO Julian Adams Ph.D. said, "FDA clearance of our IND for the cryopreserved formulation of GDA-201 represents a significant milestone for the company and reflects our team's expertise in the development of NAM-enabled cell therapies. Previously announced data from an investigator-sponsored study evaluating the fresh formulation of GDA-201 demonstrated...